Napa’s Finest Come to Newport Beach, Led by Vintner Chair Peter Michael Winery NEWPORT BEACH, California (February 5, 2026) – CureDuchenne, a global leader in accelerating research and care for Duchenne muscular dystrophy, has […]
In 2018, CureDuchenne was the only Duchenne-focused organization to invest in Avidity Biosciences, recognizing the potential of their novel RNA-targeting approach for individuals with Duchenne muscular dystrophy long before it reached clinical trials. […]
Record-Breaking Impact During World Duchenne Awareness Month Each September, World Duchenne Awareness Month shines a spotlight on the urgent needs and powerful momentum within our community. This year, CureDuchenne’s Physical and Occupational Therapy Certification […]
CureDuchenne Fuerza 2025, hosted by the CureDuchenne International Program on October 25, 2025, brought together more than 400 attendees with the goal of improving care for individuals with Duchenne and Becker muscular dystrophy. Over […]
Full-Day Conference Will Bring Education, Support, and Connection to Families and Healthcare Providers Serving the Duchenne and Becker Community Newport Beach, Calif., September 18, 2025 — CureDuchenne, a global leader […]
Event Proceeds Will Advance Research and Support the CureDuchenne Clinic within the Neuromuscular Program at Rady Children’s Health Orange County NEWPORT BEACH, California (September 19, 2025) – CureDuchenne, a global […]
Ribbon-Cutting Ceremony Marks a Major Step Forward in Expanding Access to Advanced Care and Cutting-Edge Treatment for Families Across Southern California NEWPORT BEACH, Calif. (September 15, 2025) – CureDuchenne and […]
Top Dallas Chefs and Napa Valley Wines Unite to Support Groundbreaking Research for Duchenne Muscular Dystrophy Dallas, TX – August 21, 2025 – CureDuchenne, a leading nonprofit dedicated to finding […]
Edgewise Therapeutics, which received early funding from CureDuchenne, has reported positive results in its sevasemten program for Becker and Duchenne muscular dystrophies. New open-label data in Becker from the MESA trial demonstrated […]
